China at forefront of next oncology revolution, says GlobalData
Solid tumors are emerging as the next frontier for CAR-T innovation, with China poised to deliver the world’s first approved CAR-T therapy for gastric cancer.
The anticipated approval signals a pivotal shift in oncology treatment, expanding CAR-T beyond hematological malignancies and intensifying competition in the rapidly evolving solid tumor landscape, where early clinical success, regulatory momentum, and market access strategies will define long-term leadership, according to intelligence and productivity platform. GlobalData
Reportedly, CARsgen Therapeutics’ (HKEX: 2171) satricabtagene autoleucel (satri-cel, CT041), a ground-breaking CAR-T therapy targeting Claudin 18.2 for advanced gastric and gastroesophageal cancers, is currently under the National Medical Products Administration (NMPA) review. It is expected to become available in China in the first half of 2026.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze